CPIC assigns CPIC levels to genes/drugs with (1) PharmGKB Clinical Annotation Levels of Evidence of 1A, 1B, 2A and 2B, or (2) a PharmGKB PGx level for FDA-approved drug labels of “actionable pgx”, “genetic testing recommended”, or “genetic testing required”, or (3) based on nomination to CPIC for consideration.
The levels (A, B, C, and D) assigned are subject to change and are initially given a “provisional” CPIC level status; only those gene/drug pairs that have been the subject of guidelines have had sufficient in-depth review of evidence to provide definitive CPIC level assignments (“final” CPIC level status).
Note that only CPIC level A and B gene/drug pairs have sufficient evidence for at least one prescribing action to be recommended. CPIC level C and D gene/drug pairs are not considered to have adequate evidence or actionability to have prescribing recommendations.
- View CPIC’s process for assigning CPIC levels
- View CPIC’s levels for genes/drugs
- View CPIC’s process for prioritizing CPIC guidelines
CPIC invites feedback on existing and planned gene/drug guidelines.